An important question is which cancers would potentially benefit from interfering with PI3K activity to block CIN, and whether such an approach would require the maximum-tolerated doses of PI3K inhibitors that are currently used in the clinic. This evidence concerns the gene PIK3CD and cervical squamous intraepithelial neoplasia.